Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

0.3153
-0.0195-5.82%
Post-market: 0.32000.0047+1.49%19:36 EDT
Volume:796.82K
Turnover:257.53K
Market Cap:14.53M
PE:-0.23
High:0.3395
Open:0.3200
Low:0.3142
Close:0.3348
Loading ...

Company Profile

Company Name:
Cellectar Biosciences
Exchange:
NASDAQ
Establishment Date:
2002
Employees:
11
Office Location:
100 Campus Drive,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Directors

Name
Position
Douglas J. Swirsky
Chairman of the Board and Director
James Caruso
President, Chief Executive Officer and Director
Asher Chanan Khan
Director
Frederick W. Driscoll
Director
John Neis
Director
Stefan D. Loren
Director
Stephen A. Hill
Director

Shareholders

Name
Position
James Caruso
President, Chief Executive Officer and Director
Dov Elefant
Vice President and Chief Financial Officer
Jarrod Longcor
Chief Business Officer
John E. Friend II
Vice President and Chief Medical Officer